PCRX
the council passes — AVOIDPACIRA BIOSCIENCES, INC.·Healthcare
The quality and the price don't line up.
48/100D
Price at last run$25.65as of Jul 8, 2026
healthcare✕Why not
The honest case against — what most tools hideMain riskvaluation stretched
Demanding valuationTrading at ~160× earnings — little room for error.
Quality concernReturns on capital are below what we want to own.
What keeps us out
- Paying up here — we'd want a better entry price.
- Growth slowing while the multiple stays rich.
Patience price & distance
as of Jul 8, 2026 runThe patience price is where value discipline would let the council in — deliberately strict: we'd rather miss ten winners than own one loser.
Catalyst
none yet
A catalyst is a plausible reason the gap could close — never a certainty.